Vimarsana
Biggest News Aggregation in the World

Page 23 - Unctional News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Unctional. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Unctional Today - Breaking & Trending Today

Cannibble Foodtech Ltd: Cannibble Announces LOI for Acquisition of Eshbal Functional Foods an Israeli Food Tech Manufacturer - Vimarsana News

Cannibble Foodtech Ltd: Cannibble Announces LOI for Acquisition of Eshbal Functional Foods an Israeli Food Tech Manufacturer

Rosh Haayin, Israel--(Newsfile Corp. - August 29, 2022) - Cannibble Foodtech Ltd., (CSE: PLCN) ("Cannibble" or the "Company"), an Israeli food-tech company that develops and manufactures food and beverage

Stylishly Protected: Distil's MagLock Sunglasses are as Stylish as They are Functional - Vimarsana News

Stylishly Protected: Distil's MagLock Sunglasses are as Stylish as They are Functional

Distil MagLock Sunglasses: keeping your eyes safe and your sunglasses even safer Distil's MagLock sunglasses aren't your ordinary pair of sunglasses.

Vietnam reports rise in fake medicine distribution | Borneo Bulletin Online - Vimarsana News

Vietnam reports rise in fake medicine distribution | Borneo Bulletin Online

THE STAR – More fraudsters are using online platforms, social networks and messaging services to sell and distribute fake medicines, according to Chairman of the Advisory Council for the Registration of Circulation of Drugs and Medical Ingredients Le Van Truyen. The chairman was speaking at a seminar on fake medicines and functional foods. According to […]

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022 - Vimarsana News

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022

Additional data showed numerical improvement in activities of daily living , a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified... | August 3, 2022

Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon(R) Platform - Vimarsana News

Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon(R) Platform

EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon system for antibody discovery,as well as cell and gene therapy and cell line development research. Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical scientists have been developing significant expertise in using the Berkeley Lights technology and workflows. Specifically, the Beacon Platform has enabled them to expand their a...

Related Topics:
United StatesYue GengOtsuka PharmaceuticalsPrnewswire Berkeley Lights IncBerkeley LightsBeacon PlatformOtsuka PharmaceuticalBerkeley Lights PlatformJuly 26022 Prnewswire Berkeley LightsNc Nasdaq Bli A Leader In Digital Cell BiologyOday Announced Otsuka PharmaceuticalsA Leading Pharmaceutical CompanyAs Implemented The Use Of Berkeley Lights Beacon System For Antibody DiscoveryAs Well Cell And Gene Therapy Line Development Research Since Acquiring The Beacon Platform In October 2021Tsuka Pharmaceutical Scientists Have Been Developing Significant Expertise In Using The Berkeley Lights Technology And Workflows SpecificallyHe Beacon Platform Has Enabled Them To Expand Their Antibody Discovery Capacity Beyond Traditional Hybridoma Techniques On Top Of The ExpertiseTsuka Will Be Leveraging The Beacon Technology And Workflows For Use In Challenging Field Of Cell Gene Therapy With System ResearchHey Can Work Rapidly And Efficiently Towards New Discoveries Yue GengJh DEneral Manager And Senior Vice President Of The Platform Business At Berkeley LightsUot Otsuka Pharmaceutical And Their Scientists Area Great Example Ofa Team Fully Leveraging The Beacon Platform Capabilities In Multiple Scientific Disciplines They Have Demonstrated Themselves Asa Leader Competitive Pharma Market Through Dedication Learning Advanced Technologies Systems We Value Partnership To Research Using Our For Success Of Customers Quot About Berkeley Lights Isa Leading Digital Cell Biology Company Focused On Enabling Accelerating Rapid Development Commercialization Biotherapeutics Other Based Products Captures Deep PhenotypicNd Genotypic Information For Thousands Of Single Cells In Parallel And Can Also Deliver The Live Biology Customers Desire Form Best Our Platform Isa Fully IntegratedNd To End Solution